An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites
Objectives This review highlights both the physicochemical characteristics of the
nanocarriers (NCs) and the physiological features of tumour microenvironment (TME) to …
nanocarriers (NCs) and the physiological features of tumour microenvironment (TME) to …
The delivery of therapeutic oligonucleotides
RL Juliano - Nucleic acids research, 2016 - academic.oup.com
The oligonucleotide therapeutics field has seen remarkable progress over the last few years
with the approval of the first antisense drug and with promising developments in late stage …
with the approval of the first antisense drug and with promising developments in late stage …
Materials for non-viral intracellular delivery of messenger RNA therapeutics
Though therapeutics based on messenger RNA (mRNA) have broad potential in
applications such as protein replacement therapy, cancer immunotherapy, and genomic …
applications such as protein replacement therapy, cancer immunotherapy, and genomic …
Polymeric Nanoparticles for Drug Delivery
MA Beach, U Nayanathara, Y Gao, C Zhang… - Chemical …, 2024 - ACS Publications
The recent emergence of nanomedicine has revolutionized the therapeutic landscape and
necessitated the creation of more sophisticated drug delivery systems. Polymeric …
necessitated the creation of more sophisticated drug delivery systems. Polymeric …
RNAi therapeutic and its innovative biotechnological evolution
Abstract Recently, United States Food and Drug Administration (FDA) and European
Commission (EC) approved Alnylam Pharmaceuticals' RNA interference (RNAi) therapeutic …
Commission (EC) approved Alnylam Pharmaceuticals' RNA interference (RNAi) therapeutic …
MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma
AF Ibrahim, U Weirauch, M Thomas, A Grünweller… - Cancer research, 2011 - AACR
MicroRNAs (miRNA) aberrantly expressed in tumors may offer novel therapeutic
approaches to treatment. miR-145 is downregulated in various cancers including colon …
approaches to treatment. miR-145 is downregulated in various cancers including colon …
Glutathione-depletion mesoporous organosilica nanoparticles as a self-adjuvant and co-delivery platform for enhanced cancer immunotherapy
Silica based nanoparticles have emerged as a promising vaccine delivery system for cancer
immunotherapy, but their bio-degradability, adjuvanticity and the resultant antitumor activity …
immunotherapy, but their bio-degradability, adjuvanticity and the resultant antitumor activity …
Intelligent nanomaterials for medicine: carrier platforms and targeting strategies in the context of clinical application
Nanomedical approaches are a major transforming factor in medical diagnosis and
therapies. Based on important earlier work in the field of liposomal drug delivery and …
therapies. Based on important earlier work in the field of liposomal drug delivery and …
Progress toward in vivo use of siRNAs-II
GR Rettig, MA Behlke - Molecular therapy, 2012 - cell.com
RNA interference (RNAi) has been extensively employed for in vivo research since its use
was first demonstrated in mammalian cells 10 years ago. Design rules have improved, and it …
was first demonstrated in mammalian cells 10 years ago. Design rules have improved, and it …
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens
F Wegmann, KH Gartlan, AM Harandi… - Nature …, 2012 - nature.com
Protection against mucosally transmitted infections probably requires immunity at the site of
pathogen entry 1, yet there are no mucosal adjuvant formulations licensed for human use …
pathogen entry 1, yet there are no mucosal adjuvant formulations licensed for human use …